Allergan Medical Sustainability Profile
Allergan Medical, a subsidiary of AbbVie, is a leading player in the global medical aesthetics industry, headquartered in the United States. Founded in 1948, the company has established itself as a pioneer in innovative treatments, particularly in the fields of facial aesthetics, breast aesthetics, and eye care. With a strong presence in North America, Europe, and Asia, Allergan Medical is renowned for its flagship products, including the popular Botox® and Juvederm® lines, which are distinguished by their advanced formulations and proven efficacy. The company has achieved significant milestones, such as the expansion of its product portfolio and the introduction of cutting-edge technologies in aesthetic medicine. Allergan Medical's commitment to quality and innovation has solidified its position as a market leader, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does Allergan Medical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Allergan Medical's score of 36 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Allergan Medical, headquartered in the US, currently does not have specific carbon emissions data available for recent years. The organisation is a current subsidiary of AbbVie Inc., which influences its climate commitments and emissions reporting. As part of its corporate family, Allergan Medical's climate initiatives and targets are cascaded from AbbVie Inc. at a level 2 relationship. While Allergan Medical does not report its own emissions figures, it is aligned with AbbVie Inc.'s sustainability efforts, which include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). These initiatives aim to establish robust frameworks for reducing greenhouse gas emissions across various scopes, including Scope 1, 2, and 3 emissions. Despite the absence of specific reduction targets or achievements for Allergan Medical, the overarching commitments from AbbVie Inc. reflect a dedication to addressing climate change and reducing carbon footprints. The company is actively engaged in initiatives that promote sustainability and environmental responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2005 | 2010 | 2011 | 2012 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 28,218,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 59,189,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Allergan Medical's Industry?
How Carbon Intensive is Allergan Medical's Location?
Allergan Medical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Allergan Medical has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
